Targeting DNA topoisomerases: past & future

References

[1] Champoux JJ.DNA topoisomerases: structure, function, and mechanism.Annu Rev Biochem2001;70:369-413

[2] Gmeiner WH,Haber AO.Improved antitumor activity of the fluoropyrimidine polymer CF10 in preclinical colorectal cancer models through distinct mechanistic and pharmacologic properties.Mol Cancer Ther2021;20:553-63 PMCID:PMC8201368

[3] Lotz C.The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance.Cancer Drug Resist2020;3:149-60

[4] Elton TS,Yalowich JC.Effects of DNA topoisomerase IIα splice variants on acquired drug resistance.Cancer Drug Resist2020;3:161-70 PMCID:PMC7304410

[5] Soren BC,Ottaviani A,Fiorani P.Topoisomerase IB: a relaxing enzyme for stressed DNA.Cancer Drug Resist2020;3:18-25

[6] Wall ME,Cook CE,McPhail AT.Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata.J Am Chem Soc1966;88:3888-90

[7] Gmeiner WH.Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs.Cancer Drug Resist2019;2:994-1001 PMCID:PMC6953902

[8] Wang JC.Interaction between DNA and an Escherichia coli protein omega.J Mol Biol1971;55:523-33

[9] Yang SW,Huizenga BN,Yao KC.A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases.Proc Natl Acad Sci U S A1996;93:11534-9 PMCID:PMC38092

[10] Brettrager EJ.Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts.Cancer Drug Resist2019;2:1153-63 PMCID:PMC6929713